

Date: 30<sup>th</sup> January, 2019

To,  
The Manager,  
The BSE Limited  
1st Floor, Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai - 400 001

Dear Sir/Madam,

**Sub:** Outcome of Board Meeting

With reference to the captioned matter, the exchange is hereby informed that the Board of Directors of Alembic Limited at its meeting held today has approved the Unaudited Financial Results of the Company for the quarter and nine months period ended 31<sup>st</sup> December, 2018.

Further, we enclose herewith Limited Review Report by Statutory Auditors on Unaudited Financial Results for the quarter and nine months period ended 31<sup>st</sup> December, 2018.

The time of commencement of the Board Meeting was 3:30 p.m. and the time of conclusion was 4:55 p.m.

Thanking you,

Yours faithfully,

**For Alembic Limited**

  
**Drigesh Mittal**  
**Company Secretary**



Encl.: As above

**ALEMBIC LIMITED**

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003. • TEL : (0265) 2280550, 2280880 • FAX : (0265) 2281229  
Website : www.alembic-india.com • E-mail : alembic@alembic.co.in • CIN : L26100GJ1907PLC000033

An ISO 14001 Company

**Statement of Standalone Unaudited Financial Results for the Quarter and Nine Months Ended 31st December, 2018**

Rs. in Lakhs

Sr. No.	Particulars	Quarter Ended			Nine Month Ended		Year Ended
		31.12.2018 (Unaudited)	30.09.2018 (Unaudited)	31.12.2017 (Audited)	31.12.2018 (Unaudited)	31.12.2017 (Audited)	31.03.2018 (Audited)
1	Revenue from Operations	2,431	3,356	2,993	10,239	9,209	12,530
2	Other Income	158	2,422	401	2,710	3,383	3,701
3	<b>Total Income</b>	<b>2,589</b>	<b>5,778</b>	<b>3,394</b>	<b>12,950</b>	<b>12,592</b>	<b>16,231</b>
4	<b>Expenses</b>						
	Cost of Materials Consumed	959	1,806	1,606	3,311	3,351	3,986
	Cost of Construction	278	400	791	2,105	2,201	3,078
	Changes in Inventories of Finished Goods and WIP	51	(596)	(622)	221	278	809
	Employee Benefit Expenses	500	662	444	1,646	1,452	2,074
	Finance Costs	5	4	3	16	14	17
	Depreciation and amortisation expense	71	56	81	192	317	378
	Other Expenses	335	449	341	1,187	818	1,472
	<b>Total Expenses</b>	<b>2,199</b>	<b>2,782</b>	<b>2,644</b>	<b>8,678</b>	<b>8,431</b>	<b>11,813</b>
5	<b>Profit Before Tax</b>	<b>390</b>	<b>2,996</b>	<b>750</b>	<b>4,272</b>	<b>4,161</b>	<b>4,417</b>
6	<b>Tax Expenses</b>						
	Current Tax	72	147	150	409	377	431
	Deferred Tax	(0)	(86)	44	(67)	72	30
	Short / (Excess) Provision of earlier years	(5)	-	-	(21)	-	(222)
7	<b>Net Profit after tax for the Period</b>	<b>324</b>	<b>2,935</b>	<b>556</b>	<b>3,950</b>	<b>3,712</b>	<b>4,178</b>
8	<b>Other Comprehensive Income</b>						
	(i) Items that will not be reclassified to Profit or Loss	(1,240)	3,368	3,487	3,070	4,013	4,443
	(ii) Income tax relating to items that will not be reclassified to Profit or Loss	143	160	177	169	(7)	114
9	<b>Total Comprehensive Income for the Period</b>	<b>(774)</b>	<b>6,464</b>	<b>4,220</b>	<b>7,190</b>	<b>7,719</b>	<b>8,735</b>
10	Earnings per equity share (FV Rs. 2/- per share) Basic & Diluted (In Rs.)	0.13	1.14	0.21	1.53	1.39	1.56



Alembic Limited  
Segment wise Standalone Revenue and Results

Rs. In Lakhs

Sr. No.	Particulars	Quarter Ended			Nine Month Ended		Year Ended
		31.12.2018 (Unaudited)	30.09.2018 (Unaudited)	31.12.2017 (Audited)	31.12.2018 (Unaudited)	31.12.2017 (Audited)	31.03.2018 (Audited)
1	<b>Segment Revenue</b>						
	Revenue from Operations						
	a. Active Pharmaceutical Ingredients Business	1,446	1,865	1,577	5,265	5,096	6,636
	b. Real Estate Business	985	1,491	1,416	4,974	4,112	5,893
	<b>Total Income from Operations (Net)</b>	<b>2,431</b>	<b>3,356</b>	<b>2,993</b>	<b>10,239</b>	<b>9,209</b>	<b>12,530</b>
2	<b>Segment Results (Profit (+)/ Loss (-) before Taxes and interest from each segment)</b>						
	a. Active Pharmaceutical Ingredients Business	13	21	267	133	411	26
	b. Real Estate Business	289	653	346	1,670	863	1,319
	<b>Total</b>	<b>303</b>	<b>674</b>	<b>612</b>	<b>1,802</b>	<b>1,274</b>	<b>1,346</b>
	Unallocable Income and Expenditure						
	(i) Interest Expense	(5)	(4)	(3)	(16)	(14)	(17)
	(ii) Dividend Income and Gain on Financial asset at Fair Value	59	2,293	113	2,386	2,851	2,940
	(iii) Other Income / (Expense)	34	33	26	99	50	148
	<b>Total Profit Before Tax</b>	<b>390</b>	<b>2,996</b>	<b>750</b>	<b>4,272</b>	<b>4,161</b>	<b>4,417</b>
3	<b>Segment Assets</b>						
	a. Active Pharmaceutical Ingredients Business	17,809	18,020	19,544	17,809	19,544	17,189
	b. Real Estate Business	8,635	8,708	7,523	8,635	7,523	7,426
	c. Unallocated	23,687	25,723	25,805	23,687	25,805	27,581
	<b>Total</b>	<b>50,131</b>	<b>52,451</b>	<b>52,871</b>	<b>50,131</b>	<b>52,871</b>	<b>52,196</b>
4	<b>Segment Liabilities</b>						
	a. Active Pharmaceutical Ingredients Business	3,121	3,222	2,908	3,121	2,908	2,071
	b. Real Estate Business	3,036	4,274	4,685	3,036	4,685	4,309
	c. Unallocated	734	941	1,426	734	1,426	947
	<b>Total</b>	<b>6,892</b>	<b>8,437</b>	<b>9,019</b>	<b>6,892</b>	<b>9,019</b>	<b>7,328</b>

**Notes:**

- The above results have been reviewed by Statutory Auditors, recommended by Audit Committee and approved by the Board of Directors of the Company.
- The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.
- The Board of Directors of the Company had at their meeting held on 3<sup>rd</sup> November, 2018 inter alia approved the Composite Scheme of Arrangement comprising of the transfer and vesting of the Identified Real Estate Undertaking of Alembic Limited ('the Company' or 'the First Demerged Company' or 'Alembic'), comprising of a real estate development project alongwith related real estate interest and Project Management Consultancy business into Shreno Limited ('the First Transferee Company' or 'the Second Demerged Company' or 'Shreno') and transfer and vesting of Engineering Division and Investment Division of Shreno Limited into Nirayu Private Limited ('the Second Transferee Company' or 'Nirayu') and their respective shareholders with effect from the Appointed Date i.e. 1<sup>st</sup> November, 2018. The Scheme is subject to requisite statutory and regulatory approvals and sanction by the respective shareholders of each of the Companies involved in the Scheme. Pending receipt of statutory approvals, income / expenses of inter-company transactions involving the businesses affected by the Scheme amounting to a surplus of Rs. 110.29 lakhs have not been considered in the above results by the Company.

For Alembic Limited

Place : Vadodara  
Date : 30th January, 2019



*(Signature)*  
Nirayu Amin  
Chairman


**Limited Review Report****To the Board of Directors of Alembic Limited**

1. We have reviewed the accompanying statement of unaudited standalone Ind-AS financial results of **Alembic Limited** ("the Company") for the quarter/nine months ended 31st December, 2018 ("the Statement") together with the notes thereon attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which has been initialed by us for identification purposes.
2. This Statement which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement.
4. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited standalone Ind-AS financial results has not disclosed the information required to be disclosed in terms of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **C N K & Associates LLP**

Chartered Accountants

Firm Registration No. 101961W/W-100036

  
Himanshu Kishnadwala

Partner

Membership No.37391

Place: Vadodara

Date:30<sup>th</sup> January, 2019